Should You Buy Pacific Biosciences Stock Now?

May 27. 2023. 8 mins read

Earlier this month we dissected the ongoing battle between investor activist Carl Icahn and the second-biggest holding in our Nanalyze Disruptive Tech Portfolio – Illumina (ILMN). The latest round just came to an end on May 25 when shareholders approved one of Icahn’s three hand-picked nominees for the gene-sequencing company’s board of directors, ousting the chairman in the process. How this will help right the ship after a series of disastrous decisions by Illumina management, which has caused the company to shed some $50 billion in value since August 2021 when it announced plans to acquire the liquid biopsy company GRAIL, remains to be seen. The best-case scenario is that Illumina drops its pursuit of ill-advised acquisitions and focuses on maintaining its market leadership in gene-sequencing technology. Because Icahn isn’t the only barbarian banging at Illumina’s gates.

Taking the Lead on Long-Read Sequencing

Click for company website

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.